| ¿µ¹® | extirpation, removal | ÇÑ±Û | ÀûÃâ¼ú, Á¦°Å¼ú |
|---|---|---|---|
| ¼³¸í | ½ÅüºÎºÐÀ¸·ÎºÎÅÍ Á¶Á÷À» ²ôÁý¾î³»°Å³ª Àß¶ó³»´Â °Í. ¶ß°Å¿î Ä®À̳ª ·¹ÀÌÀú ¶Ç´Â ³¯Ä«·Î¿î ±â±¸¸¦ ½á¼ Àý°³Çϰųª ²ø¾î´ç±â°Å³ª ÈíÀÔÀ» ÅëÇØ ½ÅüÁ¶Á÷À̳ª °ü±¸Á¶ÀÇ ³»°¿¡ ÀÖ´Â °íÇüÁúÀ» ²ôÁý¾î³»´Â °Í. |
||
| ¿µ¹® | antiglobulin antibody | ÇÑ±Û | Çױ۷κҸ°Ç×ü |
|---|---|---|---|
| ¼³¸í | Ç×ü¿¡ ´ëÇÑ Ç×ü, Áï Æ¯Á¤ Ç×ü¿Í °áÇÕÇÒ ¼ö ÀÖ´Â Ç×ü. ´ë°³ Àΰ£ÀÇ Ç×ü¸¦ Áã¿¡ ÁÖ»çÇÏ¿© Áã·Î ÇÏ¿©±Ý Àΰ£ Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¸¸µé°Ô ÇÑ´Ù(Áã¿¡ À־ Àΰ£ÀÇ Ç×üµµ ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°ÁúÀ̹ǷÎ). À̰ÍÀº ¿©·¯ °¡Áö ½ÇÇè¿¡¼ Àΰ£ÀÇ Æ¯Á¤Ç×ü¸¦ °ËÃâÇϴµ¥ ÀÌ¿ëÇÑ´Ù. |
||
| ¿µ¹® | antibody | ÇÑ±Û | Ç×ü |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡¼ ¸é¿ª¿¡ °ü°èÇÏ´Â ¹°Áú. ¿ÜºÎ¿¡¼ µé¾î¿Â ¹°Áú°ú ²À ¸Â°Ô °áÇÕÀ» ÇÏ¿©¼ ±× ¹°ÁúÀÇ »ý¹°ÇÐÀû Ȱµ¿À» ¾ïÁ¦Çϰųª ÆÄ±«Çϰųª »ç¶÷ÀÇ ´Ù¸¥ ¸é¿ª¼¼Æ÷·Î ÇÏ¿©±Ý °ø°ÝÇϱ⠿ëÀÌÇÏ°Ô ÇØÁÖ´Â ±â´ÉÀ» °¡Áö°í ÀÖ´Ù. Ç×ü´Â ¸é¿ª±Û·ÎºÎ¸°À̶ó´Â °ÍÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ°í ±× ÇüÅ¿¡ µû¶ó IgA, IgE, IgG, IgDµîÀ¸·Î ³ª´«´Ù. |
||
| ROP | removal of pins or plates; removal of plaster [of Paris]; retinopathy of prematurity; right occipito... |
|---|---|
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| ECCO2R | extracorporeal carbon dioxide removal |
| rem | removal |
| ROM | range of motion; read only memory; reduction of movement; regional office manual; removal of metal [... |
| BNR | Biological Nutrient Removal |
|---|---|
| ECCO2R | Extracorporeal CO2 removal |
| NAb | 1-neutralizing-antibody |
| AChR-AB | Acetylcholine Receptor Antibody |
| APA | Anti phospholipid antibody |
| blood component removal | Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor. (12 Dec 1998) |
|---|---|
| lumbar disk removal | A surgical procedure which is designed to relieve pressure on the spinal cord or nerve root that is being caused by a slipped or herniated disk in the lumbar spine. This procedure is also used in the treatment of spinal stenosis. This procedure includes removal of a portion of the bone comprising a vertebra. Recovery is generally 7-10 days. An alternative to this is a micro-disc surgery. (27 Sep 1997) |
| affinity antibody | The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible. (05 Mar 2000) |
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|